Annexon Inc Total Liabilities
Annexon Inc total liabilities. Based on the latest financial reports, Annexon Inc (ANNX) has total liabilities worth $60.01 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Annexon Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Annexon Inc (2017–2025)
Total liabilities of Annexon Inc from 2017 to 2025. This chart illustrates how Annexon Inc's total liabilities have evolved over time, based on quarterly financial data.
Annexon Inc Competitors by Total Liabilities
The table below lists competitors of Annexon Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jilin Yatai Group Co Ltd
SHG:600881
|
China | CN¥40.25 Billion |
|
Hubei Century Network Technology Co Ltd
SHE:300494
|
China | CN¥163.70 Million |
|
Guangdong Meiyan Jixiang Hydropower Co Ltd
SHG:600868
|
China | CN¥916.96 Million |
|
Zhengzhou Coal Industry & Electric Power Co Ltd
SHG:600121
|
China | CN¥11.21 Billion |
|
Anhui Sierte Fertilizer Industry Ltd Co
SHE:002538
|
China | CN¥1.02 Billion |
|
Scanfil Oyj
HE:SCANFL
|
Finland | €464.90 Million |
|
Navigator Global Investments Ltd
AU:NGI
|
Australia | AU$164.23 Million |
|
Shandong Mining Machinery Group Co Ltd
SHE:002526
|
China | CN¥2.05 Billion |
Liability Composition Analysis (2017–2025)
This chart breaks down Annexon Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ANNX asset base.
Liquidity & Leverage Metrics
Annexon Inc Total Liabilities Ratios Explained
Annexon Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.32 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Annexon Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Annexon Inc (2017–2025)
The table below shows the annual total liabilities of Annexon Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $65.92 Million | +15.72% |
| 2024-12-31 | $56.97 Million | +20.90% |
| 2023-12-31 | $47.12 Million | -12.59% |
| 2022-12-31 | $53.90 Million | -2.23% |
| 2021-12-31 | $55.13 Million | +372.50% |
| 2020-12-31 | $11.67 Million | +83.23% |
| 2019-12-31 | $6.37 Million | -37.99% |
| 2018-12-31 | $10.27 Million | -80.99% |
| 2017-12-31 | $54.03 Million | -- |
About Annexon Inc
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase… Read more